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Abstract: Glycaemic control (GC) has been associated with improved outcomes in critically ill patients. 
However, inter- and intra- patient metabolic variability significantly increase the risk of hypoglycaemia 
when using insulin to control glycaemia. Model-based protocols often identify key physiological 
parameters from patient data, and demonstrated safe and effective GC. Based on recent studies showing 
gender difference in insulin secretion, this study uses retrospective data to identify whether there exists a 
difference in sexes in metabolic stress response, and thus in how personalised GC is given. 
Retrospective data from 145 ICU patients under GC who started GC in the first 12 hours of ICU stay are 
used. Insulin sensitivity (SI) is identified hourly, as well as the hour-to-hour percentage change in SI 
(%ΔSI). Differences between males and females SI and %ΔSI over 6-h blocks are compared using 
hypothesis and equivalence testing. A difference in SI levels would suggest a difference in metabolic 
stress response to insult, while a difference in %ΔSI levels would suggest a resulting difference in the 
difficulty to control. 
Results show females are significantly more insulin resistant than males and not equivalent, suggesting 
stronger stress response to insult induced stress. Metabolic variability is equivalent in both groups, 
advocating GC safety and efficacy should be similar between males and females, despite potential higher 
insulin rates required for females. 
This study is the first to suggest potential gender differences in the metabolic stress response. 
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1. INTRODUCTION 
Increased insulin resistance and excessive glucose production 
are common responses to severe injury in intensive care unit 
(ICU) patients (McCowen et al., 2001), causing abnormal 
elevated blood glucose (BG) concentrations associated with 
increased morbidity and mortality (Krinsley, 2003). 
Glycaemic control (GC), using insulin therapy to reduce BG 
levels to safer ranges, is thus essential for these patients. 
While everyone agrees GC should be used to control 
glycaemia below the renal glycosuria threshold (10.0 mmol/L 
or 180 mg/dL), the optimal target band remains a debate 
(Chase et al., 2017; Gunst et al., 2016; Krinsley, 2018; 
Preiser et al., 2016).  
Many studies showed improved outcomes associated with 
lower, normoglycaemic, ranges (Chase et al., 2008b; 
Krinsley, 2004; Reed et al., 2007; Van den Berghe et al., 
2001). However, many others failed to replicate the results 
(Brunkhorst et al., 2008; Finfer et al., 2009; Finfer et al., 
2012; Preiser et al., 2009). Chase (Chase et al., 2010) 
provided an analysis indicating GC had to be achieved for 
virtually all patients to show potential benefit, which many 
studies failed to do. A later study showed inter- and intra- 
patient variability and its evolution made this goal hard to 
achieve safely and effectively (Chase et al., 2011b; Pretty et 
al., 2012). In particular, the associated increased risk of 
hypoglycaemia due to patient variability in the response to 
insulin when targeting lower ranges being potentially more 
harmful than beneficial. Thus, guidelines now recommend 
targeting higher, broader ranges and thus permissive 
hyperglycaemia (Krinsley, 2018; Singer et al., 2019). 
More recently, independent studies have introduced new 
considerations. Patient-specific, model-based GC protocols 
have shown that safe and effective control for all patients is 
possible, despite targeting lower ranges (Mesotten et al., 
2017; Stewart et al., 2016). Those ranges are associated with 
improved outcomes (Krinsley et al., 2015; Penning et al., 
2014; Penning et al., 2015; Signal et al., 2012). Typically, 
these methods use key identified, patient-specific 
physiological parameters to dose insulin (Chase et al., 
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2011a). They can thus better account for inter- and intra- 
patient metabolic variability (Chase et al., 2019; Chase et al., 
2018), the main factor making GC hard to achieve safely.  
More specifically, it has been shown GC is not a function of 
severity of patient condition, patient metabolic condition or 
diabetes status, or outcome, suggesting all patients should 
benefit given equal quality of control (Uyttendaele et al., 
2017). Protocol design is thus the determining factor in GC, 
where poorly designed protocols with demonstrated low 
compliance have wrongly blamed lower glycaemic targets for 
increased hypoglycaemia (Uyttendaele et al., 2019b). Safe, 
effective control must thus be achieved for all patients before 
making conclusions on the clinical impact of GC. 
Given survivors and non-survivors have been shown to be 
equally controllable due to having equivalent metabolic 
variability (Uyttendaele, et al., 2017), it is possible other 
parameters could influence control if differences in patient-
specific metabolic stress response existed. In particular, 
studies have reported differences in insulin resistance, insulin 
secretion, glucose effectiveness, and endogenous glucose 
production, between genders (Basu et al., 2006; Geer et al., 
2009; Soeters et al., 2007). In neonatal ICU infants, girls 
were found to be more insulin resistant than boys given their 
higher endogenous insulin secretion (Dickson et al., 2015a; 
Dickson et al., 2015b).  
This study examines whether differences in insulin resistance 
and its variability also exist in adult ICU patients, and if it 
has an impact on control difficulty.  
2. METHODS 
2.1 Patient Cohort 
Retrospective clinical data from 371 patients on Specialised 
Relative Insulin Nutrition Tables (SPRINT) GC (Chase, et 
al., 2008b) are used. Only 145 patients (91 males, 54 
females) who started GC within 12h of ICU admission and 
received insulin for >24h are used. Demographics are in 
Table 1.  
Differences in age, mortality, severity of injury, ICU length 
of stay, diabetes, and GC outcomes between males and 
females are not significant. Only median BG levels achieved 
are significantly different, but this difference is small and 
does not have any clinical impact (Uyttendaele, et al., 2017).  
2.2 Model-based Insulin Sensitivity (SI) 
Insulin sensitivity (SI) is a physiological parameter, reflecting 
patient metabolic response to insulin and glucose, and, thus, 
patient metabolic stress response. In this study, patient-
specific model-based SI is identified hourly, using a clinically 
validated physiological model (Lin et al., 2011), 
schematically represented in Fig. 1. This model has been used 
in the Stochastic Targeted (STAR) GC framework, providing 
high quality of control for all patients (Evans et al., 2012; 
Stewart, et al., 2016). The model describes all the metabolic 
glucose-insulin pharmacodynamics. SI is identified from 
Table 1. Demographic data of male and female sub-
cohorts from 145 SPRINT patients. 
 Males Females P-val 
# patients 91 54  
Age 67 [57, 77] 67 [58, 74] 0.63a 
Mortality 18% 19% 1.0b 
APACHE II score 20 [16, 27] 19.5 [17, 26] 0.98a 
First day SOFA score 6 [4, 8] 5.5 [4, 8] 0.46a 
ICU length of stay (h) 108 [67, 188] 127.2 [64, 213] 0.91a 
SPRINT duration (h) 83 [46, 157] 87 [39, 167] 0.81a 
Type 2 Diabetes (%) 13 (14%) 11 (20%) 0.4b 
Cohort BG (mmol/L) 5.6 [4.9, 6.6] 5.9 [5.0, 6.9] <0.01a 
Median BG (mmol/L) 5.7 [5.2, 6.1] 6.0 [5.3, 6.4] 0.06a 
%BG 4.4-8.0 mmol/L 83 [72, 90] 82 [67, 89] 0.3a 
%BG < 4.0mmol/L 1.4 [0, 5.5] 1.4 [0, 6.9] 0.42a 
%BG < 2.2mmol/L 0 [0, 0] 0 [0, 0] / 
BG measures/day 15.8 [14.4, 17.5] 15.7 [14.5, 18.2] 0.47a 
Median insulin (U/h) 3 [2, 3] 3 [2, 3] 0.26a 
Median feed (g/h) 3.5 [2.1, 5.5] 2.8 [1.8, 3.9] <0.01a 
Median feed (%GF) 51 [30, 80] 51 [30, 75] 0.61a 
Goal Feed (g/h) 6.5 [6.5, 7.4] 5.2 [5.2, 5.7] <0.01a 
Data is given as per-patient median [IQR] where appropriate. P-values are 
computed using Wilcoxon Ranksum test (a) or Fisher exact test (b). 
clinical BG, insulin, and nutrition data using integral based 
methods (Docherty et al., 2012). 
Difficulty in control is assessed using the hour-to-hour 
change in SI levels (%ΔSI), reflecting metabolic variability 
and thus hyper- and hypo- glycaemic risk. In STAR, 
metabolic variability is used to assess risk for any given 
treatment, and to determine the optimal treatment (Evans, et 
al., 2012; Lin et al., 2008; Uyttendaele et al., 2018; 
Uyttendaele et al., 2019a). 
It is important to note a difference in SI level between males 
and females would suggest potential difference in metabolic 
stress response to injury. However, a difference in %ΔSI 
would suggest an outcome or resulting difference in the 
difficulty to control these patient cohorts. 
2.3 Protocol Comparison and Analyses 
This study analyses patient-specific SI and %ΔSI using 6-h 
blocks over the first 72h of control. Hypothesis testing is 
used to determine whether the null hypothesis of males and 
females sub-cohorts being drawn from distributions of equal 
medians against the alternative they are not can be rejected 
(p<0.05). Due to large data sample size effect, bootstrapping 
is used (Motulsky, 2014). Resampled cohorts of the same 
size of the original cohort are created, where sample are 
randomly chosen with replacement 1000 times, and the 
differences in median bootstrapped SI or %ΔSI between 
males and females are computed. If the 95% CI of these 
differences does not include zero (difference of equal 
medians = 0), the null hypothesis can be rejected (p<0.05). 
Because it is not clear whether data is independent, the 
Bonferroni correction for multiple comparison is also 
considered, where the 12 comparisons made suggest a 
significance level of p=0.004. Therefore, in this case, the 
99.6% CI of differences is considered. 
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specific metabolic stress response existed. In particular, 
studies have reported differences in insulin resistance, insulin 
secretion, glucose effectiveness, and endogenous glucose 
production, between genders (Basu et al., 2006; Geer et al., 
2009; Soeters et al., 2007). In neonatal ICU infants, girls 
were found to be more insulin resistant than boys given their 
higher endogenous insulin secretion (Dickson et al., 2015a; 
Dickson et al., 2015b).  
This study examines whether differences in insulin resistance 
and its variability also exist in adult ICU patients, and if it 
has an impact on control difficulty.  
2. METHODS 
2.1 Patient Cohort 
Retrospective clinical data from 371 patients on Specialised 
Relative Insulin Nutrition Tables (SPRINT) GC (Chase, et 
al., 2008b) are used. Only 145 patients (91 males, 54 
females) who started GC within 12h of ICU admission and 
received insulin for >24h are used. Demographics are in 
Table 1.  
Differences in age, mortality, severity of injury, ICU length 
of stay, diabetes, and GC outcomes between males and 
females are not significant. Only median BG levels achieved 
are significantly different, but this difference is small and 
does not have any clinical impact (Uyttendaele, et al., 2017).  
2.2 Model-based Insulin Sensitivity (SI) 
Insulin sensitivity (SI) is a physiological parameter, reflecting 
patient metabolic response to insulin and glucose, and, thus, 
patient metabolic stress response. In this study, patient-
specific model-based SI is identified hourly, using a clinically 
validated physiological model (Lin et al., 2011), 
schematically represented in Fig. 1. This model has been used 
in the Stochastic Targeted (STAR) GC framework, providing 
high quality of control for all patients (Evans et al., 2012; 
Stewart, et al., 2016). The model describes all the metabolic 
glucose-insulin pharmacodynamics. SI is identified from 
Table 1. Demographic data of male and female sub-
cohorts from 145 SPRINT patients. 
 Males Females P-val 
# patients 91 54  
Age 67 [57, 77] 67 [58, 74] 0.63a 
Mortality 18% 19% 1.0b 
APACHE II score 20 [16, 27] 19.5 [17, 26] 0.98a 
First day SOFA score 6 [4, 8] 5.5 [4, 8] 0.46a 
ICU length of stay (h) 108 [67, 188] 127.2 [64, 213] 0.91a 
SPRINT duration (h) 83 [46, 157] 87 [39, 167] 0.81a 
Type 2 Diabetes (%) 13 (14%) 11 (20%) 0.4b 
Cohort BG (mmol/L) 5.6 [4.9, 6.6] 5.9 [5.0, 6.9] <0.01a 
Median BG (mmol/L) 5.7 [5.2, 6.1] 6.0 [5.3, 6.4] 0.06a 
%BG 4.4-8.0 mmol/L 83 [72, 90] 82 [67, 89] 0.3a 
%BG < 4.0mmol/L 1.4 [0, 5.5] 1.4 [0, 6.9] 0.42a 
%BG < 2.2mmol/L 0 [0, 0] 0 [0, 0] / 
BG measures/day 15.8 [14.4, 17.5] 15.7 [14.5, 18.2] 0.47a 
Median insulin (U/h) 3 [2, 3] 3 [2, 3] 0.26a 
Median feed (g/h) 3.5 [2.1, 5.5] 2.8 [1.8, 3.9] <0.01a 
Median feed (%GF) 51 [30, 80] 51 [30, 75] 0.61a 
Goal Feed (g/h) 6.5 [6.5, 7.4] 5.2 [5.2, 5.7] <0.01a 
Data is given as per-patient median [IQR] where appropriate. P-values are 
computed using Wilcoxon Ranksum test (a) or Fisher exact test (b). 
clinical BG, insulin, and nutrition data using integral based 
methods (Docherty et al., 2012). 
Difficulty in control is assessed using the hour-to-hour 
change in SI levels (%ΔSI), reflecting metabolic variability 
and thus hyper- and hypo- glycaemic risk. In STAR, 
metabolic variability is used to assess risk for any given 
treatment, and to determine the optimal treatment (Evans, et 
al., 2012; Lin et al., 2008; Uyttendaele et al., 2018; 
Uyttendaele et al., 2019a). 
It is important to note a difference in SI level between males 
and females would suggest potential difference in metabolic 
stress response to injury. However, a difference in %ΔSI 
would suggest an outcome or resulting difference in the 
difficulty to control these patient cohorts. 
2.3 Protocol Comparison and Analyses 
This study analyses patient-specific SI and %ΔSI using 6-h 
blocks over the first 72h of control. Hypothesis testing is 
used to determine whether the null hypothesis of males and 
females sub-cohorts being drawn from distributions of equal 
medians against the alternative they are not can be rejected 
(p<0.05). Due to large data sample size effect, bootstrapping 
is used (Motulsky, 2014). Resampled cohorts of the same 
size of the original cohort are created, where sample are 
randomly chosen with replacement 1000 times, and the 
differences in median bootstrapped SI or %ΔSI between 
males and females are computed. If the 95% CI of these 
differences does not include zero (difference of equal 
medians = 0), the null hypothesis can be rejected (p<0.05). 
Because it is not clear whether data is independent, the 
Bonferroni correction for multiple comparison is also 
considered, where the 12 comparisons made suggest a 
significance level of p=0.004. Therefore, in this case, the 
99.6% CI of differences is considered. 
 
 
     
 
Although a difference can be statistically significant, it may 
not have a significant clinical impact (Motulsky, 2014, 2015). 
Equivalence testing is thus used to assess if a difference 
between genders, statistically significant or not, has the 
potential to change clinical decision-making. The equivalence 
range used is based on the change in SI required to exceed 
one standard deviation of BG measurement error (±9.4%) or 
cause a change in model-based insulin recommendations. 
This equivalence range thus corresponds to a change in SI of 
approximately ±15%, based on the median SI value. Further 
details are published in (Uyttendaele, et al., 2017). If the 95% 
CI (or 99.6% CI using the Bonferroni correction) of the % 
difference in medians of bootstrapped cohorts falls within the 
equivalence range, the difference in distributions can be 
considered equivalent (Motulsky, 2014). A statistically 
significant difference can thus well be within equivalence 
range, suggesting the difference is not sufficient to cause 
major clinical impact. 
Table 2. SI levels comparison between male and female 
cohorts using 6-h blocks. 
Hours 





[95%CI] difference in 
bootstrapped median 
SI (×e-5) 
Day 1  
0-5 1.5 [0.5, 2.7] 1.3 [0.5, 2.3] [0.0, 4.8] 
6-11 2.2 [1.3, 3.7] 1.8 [0.7, 3.3] [0.8, 6.6] 
12-17 3.1 [1.7, 4.8] 2.2 [1.1, 4.2] [5.3, 13.1]a 
18-23 3.3 [1.8, 5.9] 2.4 [1.5, 3.9] [4.8, 12.1]a 
Day 2  
24-29 3.3 [1.8, 5.7] 2.8 [1.6, 4.0] [1.2, 11.0] 
30-35 3.7 [2.1, 6.5] 2.7 [1.8, 4.6] [4.8, 14.1]a 
36-41 3.6 [2.0, 6.0] 2.8 [1.7, 4.3] [2.4, 14.3]a 
42-47 3.6 [2.0, 6.0] 2.9 [1.8, 4.2] [2.3, 11.1]a 
Day 3  
48-53 4.0 [2.2, 6.8] 2.9 [1.9, 4.4] [6.4, 15.9]a 
54-59 4.4 [2.4, 6.7] 3.2 [1.9, 4.8] [4.3, 15.5]a 
60-65 3.8 [2.3, 6.0] 3.2 [2.1, 4.6] [1.3, 9.7] 
66-71 3.8 [2.5, 5.7] 3.0 [2.4, 4.7] [4.1, 11.8]a 
Difference in bootstrapped median SI levels is significant (bold) if the 95% 
CI does not include the null hypothesis value of 0 (p<0.05). aDifference 
remains significant after Bonferroni correction (p<0.004). SI units: 
L/mU/min. 
Table 3. %ΔSI levels comparison between male and 






 [95%CI] difference 
in bootstrapped 
median %ΔSI (%) 
Day 1  
0-5 4.5 [-23.1, 61.3] 1.6 [-34.5, 51.1] [-9.7, 9.8] 
6-11 7.2 [-12.7, 38.7] 9.9 [-15.4, 42.0] [-9.7, 4.0] 
12-17 5.4 [-10.6, 27.4] 4.5 [-16.3, 37.6] [-8.3, 7.5] 
18-23 2.9 [-15.5, 24.2] 2.4 [-14.6, 25.0] [-4.7, 7.1] 
Day 2  
24-29 2.5 [-12.5, 22.1] 4.7 [-13.0, 24.9] [-6.9, 1.4] 
30-35 0.2 [-15.6, 23.7] 5.6 [-12.0, 24.5] [-11.0, -0.7] 
36-41 1.2 [-11.4, 16.2] 0.3 [-17.0, 16.4] [-3.4, 6.5] 
42-47 2.0 [-12.3, 19.8] 0.6 [-11.9, 18.2] [-3.7, 5.1] 
Day 3  
48-53 2.7 [-8.6, 16.3] 0.7 [-10.8, 18.7] [-2.8, 5.4] 
54-59 -0.8 [-15.0, 13.1] 1.3 [-10.2, 18.1] [-5.8, 1.9] 
60-65 1.3 [-11.0, 17.5] 4.5 [-10.0, 19.6] [-8.0, 0.3] 
66-71 1.9 [-9.6, 13.6] 1.6 [-9.0, 14.3] [-5.3, 3.4] 
Difference in bootstrapped median %ΔSI levels is significant (bold) if the 
95% CI does not include the null hypothesis value of 0 (p<0.05). 
3. RESULTS 
SI level comparison for every 6-h block and resulting 95% CI 
difference in median bootstrapped SI values are presented in 
Table 2. Equivalence testing results are shown in Fig. 1. 
Female SI is lower, and the difference with male is 
statistically significant (p<0.05) for every 6-h block (95% CI 
does not include the null hypothesis value 0). These 
differences generally remain significant using the Bonferroni 
correction (p<0.004). The difference in SI is also never 
within equivalence range. Women thus have significantly 
lower SI, and the difference are not within equivalent range, 
suggesting it has a clinical impact on decision making. 
 
Fig. 1. Equivalence testing results on SI between males and 
females for each 6-h block. Blue solid lines give equivalence 
range. Equivalence accepted if 95% CI of percentage 
difference in bootstrapped median SI values is within 
equivalence range, and rejected otherwise. 
 
Fig. 2. Equivalence testing results on %ΔSI between males 
and females for each 6-h block. Blue solid lines give 
equivalence range. Equivalence accepted if 95% CI of 
percentage difference in median bootstrapped %ΔSI values is 
within equivalence range, and rejected otherwise. 
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Considering metabolic variability, %ΔSI comparison for 
every 6-h block and resulting 95% CI difference in median 
bootstrapped %ΔSI values are in Table 3. Equivalence testing 
results are shown in Fig. 2. 
Differences in metabolic variability (%ΔSI) are never 
significant (95% CI includes the null hypothesis value 0, 
p>0.05), except one 6-h block. These differences are never 
significant when using Bonferroni correction (p>0.004). 
Additionally, these differences are always within the 
equivalence range (Fig. 2). Males and females thus have 
equivalent metabolic variability and should be equally easy 
or hard to control. 
4. DISCUSSION 
The results presented suggest two main outcomes. One based 
on SI significant difference between genders, and the second 
on equivalent variability. Specifically, females are more 
insulin resistant and have a stronger metabolic response to 
stress, and males and females are equally hard to control. 
In this retrospective cohort, male and female sub-groups 
demographics and GC outcomes are similar (Table 1). The 
only significant differences are in the overall median cohort 
BG distribution and nutrition rates achieved. However, the 
difference in BG levels is well within clinical equivalence 
(Uyttendaele, et al., 2017), and the significant difference in 
nutrition rates achieved (g/h) is explained by the difference in 
the original goal feed (GF). When comparing nutrition rates 
in terms of %GF achieved, which is based on body size, the 
difference, as expected, disappears and %GF rates are 
similar. Thus, both groups are demographically similar. 
Weight information is not available for SPRINT patients. 
However, GF is calculated starting from the 2000kcal/day 
recommended by ACCP guidelines, and then adapted for 
each patient based on sex, age, and body frame size. GF thus 
ranges from ~1025 – 2450 kcal/day. Frame size approximates 
body mass into three groups, while age captures change in 
energy demands as age increases. Thus, these metrics account 
for body mass and demand to personalise nutrition goals.  
GF (g/h) is higher for males (Table 1), as they typically have 
higher body mass, so this difference is expected. However, 
%GF is the same between the sexes, and thus overall caloric 
goals per body mass and estimated demand by age are similar 
across both cohorts. Hence, given insulin administration and 
%GF delivered are the same, it can be concluded females 
were given similar g/hr of nutrition per body weight and 
demand, but were given greater insulin per body mass or 
frame size. Specifically, %GF is normalised to mass in part; 
but insulin delivery is not. Therefore, females require more 
insulin per unit of estimated body mass to remove similar 
amounts of glucose given per unit of estimated body mass. 
Therefore, the first main outcome of this study, all else equal, 
is the significantly lower identified SI observed in females 
(Table 2), suggesting a stronger metabolic stress response 
compared to males. Additionally, the similar insulin and 
grams of dextrose per unit estimated body mass administered 
during GC, suggest higher insulin dosing per body mass was 
needed for females, further validating the lower SI levels 
identified in women. These results match neonatal ICU 
results (Dickson, et al., 2015a; Dickson, et al., 2015b), where 
preterm girls had higher insulin secretion at similar glycemia, 
and thus greater insulin resistance, than boys. 
The second main outcome is the equivalent metabolic 
variability (%ΔSI) between males and females (Fig. 2). The 
difficulty to safely and effectively control patients is inter- 
and intra-patient variability (Chase, et al., 2011b). Being 
equivalent here, suggest males and females are equally 
controllable, and thus should all benefit from safe and 
effective GC. In this SPRINT cohort, GC outcomes achieved 
were safe, effective, and achieved in a similar manner (Table 
1), supporting this result. 
Overall, the different SI levels and equivalent SI variability 
suggest GC protocol design lacking patient-specificity would 
fail to provide personalised control. Specifically, these results 
females may require higher insulin dosing for equal GC 
efficacy, at equal safety. Model-based GC approaches are 
thus needed to capture both inter- and intra- patient 
variability, and account for demographic differences between 
patients. 
In this study, patient-specific, model-based SI is identified 
from a validated physiological model (Docherty, et al., 2012; 
Lin, et al., 2011). This model has been widely shown to 
correlate well with gold standards measures (Lotz et al., 
2006; McAuley et al., 2011), but is limited by estimates of 
some parameters. The differences seen in resulting SI, all else 
equal, could be explained by two parameters: higher 
endogenous glucose production for females and/or lower 
insulin secretion. 
At equal severity (Table 1), higher than estimated 
endogenous glucose production, due to metabolic stress and 
inflammatory response to injury, would suggest higher stress 
response to injury for females. If insulin secretion is lower for 
females than estimated here, it would suggest a greater 
suppression of insulin secretion by stress hormones than for 
males. A combination of both is most likely, given the impact 
of stress response on these two parameters (Dungan et al., 
2009; McCowen, et al., 2001; Preiser et al., 2014).  
The quality of the clinical data from this study is high (Chase 
et al., 2008a; Chase, et al., 2008b). Identified SI is thus 
believed highly reflective of metabolic condition, although 
the identification of this parameter using a model can suffer 
from inaccuracies. However, the model used has been widely 
validated in clinical use (Dickson et al., 2013; Penning et al., 
2012; Stewart, et al., 2016), and shown high performance in 
the clinical ranges observed here, minimizing such potential 
inaccuracies. 
The authors did not find any analyses comparing endogenous 
glucose production and insulin secretion between sexes in 
critically ill adults. However, due to their acute condition, 
these parameters could differ in many ways. Such analyses 
would allow comparison of this study results, first to suggest 
women could be more resistant to insulin than men, 
potentially due to a greater response to insult induced stress.  
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Considering metabolic variability, %ΔSI comparison for 
every 6-h block and resulting 95% CI difference in median 
bootstrapped %ΔSI values are in Table 3. Equivalence testing 
results are shown in Fig. 2. 
Differences in metabolic variability (%ΔSI) are never 
significant (95% CI includes the null hypothesis value 0, 
p>0.05), except one 6-h block. These differences are never 
significant when using Bonferroni correction (p>0.004). 
Additionally, these differences are always within the 
equivalence range (Fig. 2). Males and females thus have 
equivalent metabolic variability and should be equally easy 
or hard to control. 
4. DISCUSSION 
The results presented suggest two main outcomes. One based 
on SI significant difference between genders, and the second 
on equivalent variability. Specifically, females are more 
insulin resistant and have a stronger metabolic response to 
stress, and males and females are equally hard to control. 
In this retrospective cohort, male and female sub-groups 
demographics and GC outcomes are similar (Table 1). The 
only significant differences are in the overall median cohort 
BG distribution and nutrition rates achieved. However, the 
difference in BG levels is well within clinical equivalence 
(Uyttendaele, et al., 2017), and the significant difference in 
nutrition rates achieved (g/h) is explained by the difference in 
the original goal feed (GF). When comparing nutrition rates 
in terms of %GF achieved, which is based on body size, the 
difference, as expected, disappears and %GF rates are 
similar. Thus, both groups are demographically similar. 
Weight information is not available for SPRINT patients. 
However, GF is calculated starting from the 2000kcal/day 
recommended by ACCP guidelines, and then adapted for 
each patient based on sex, age, and body frame size. GF thus 
ranges from ~1025 – 2450 kcal/day. Frame size approximates 
body mass into three groups, while age captures change in 
energy demands as age increases. Thus, these metrics account 
for body mass and demand to personalise nutrition goals.  
GF (g/h) is higher for males (Table 1), as they typically have 
higher body mass, so this difference is expected. However, 
%GF is the same between the sexes, and thus overall caloric 
goals per body mass and estimated demand by age are similar 
across both cohorts. Hence, given insulin administration and 
%GF delivered are the same, it can be concluded females 
were given similar g/hr of nutrition per body weight and 
demand, but were given greater insulin per body mass or 
frame size. Specifically, %GF is normalised to mass in part; 
but insulin delivery is not. Therefore, females require more 
insulin per unit of estimated body mass to remove similar 
amounts of glucose given per unit of estimated body mass. 
Therefore, the first main outcome of this study, all else equal, 
is the significantly lower identified SI observed in females 
(Table 2), suggesting a stronger metabolic stress response 
compared to males. Additionally, the similar insulin and 
grams of dextrose per unit estimated body mass administered 
during GC, suggest higher insulin dosing per body mass was 
needed for females, further validating the lower SI levels 
identified in women. These results match neonatal ICU 
results (Dickson, et al., 2015a; Dickson, et al., 2015b), where 
preterm girls had higher insulin secretion at similar glycemia, 
and thus greater insulin resistance, than boys. 
The second main outcome is the equivalent metabolic 
variability (%ΔSI) between males and females (Fig. 2). The 
difficulty to safely and effectively control patients is inter- 
and intra-patient variability (Chase, et al., 2011b). Being 
equivalent here, suggest males and females are equally 
controllable, and thus should all benefit from safe and 
effective GC. In this SPRINT cohort, GC outcomes achieved 
were safe, effective, and achieved in a similar manner (Table 
1), supporting this result. 
Overall, the different SI levels and equivalent SI variability 
suggest GC protocol design lacking patient-specificity would 
fail to provide personalised control. Specifically, these results 
females may require higher insulin dosing for equal GC 
efficacy, at equal safety. Model-based GC approaches are 
thus needed to capture both inter- and intra- patient 
variability, and account for demographic differences between 
patients. 
In this study, patient-specific, model-based SI is identified 
from a validated physiological model (Docherty, et al., 2012; 
Lin, et al., 2011). This model has been widely shown to 
correlate well with gold standards measures (Lotz et al., 
2006; McAuley et al., 2011), but is limited by estimates of 
some parameters. The differences seen in resulting SI, all else 
equal, could be explained by two parameters: higher 
endogenous glucose production for females and/or lower 
insulin secretion. 
At equal severity (Table 1), higher than estimated 
endogenous glucose production, due to metabolic stress and 
inflammatory response to injury, would suggest higher stress 
response to injury for females. If insulin secretion is lower for 
females than estimated here, it would suggest a greater 
suppression of insulin secretion by stress hormones than for 
males. A combination of both is most likely, given the impact 
of stress response on these two parameters (Dungan et al., 
2009; McCowen, et al., 2001; Preiser et al., 2014).  
The quality of the clinical data from this study is high (Chase 
et al., 2008a; Chase, et al., 2008b). Identified SI is thus 
believed highly reflective of metabolic condition, although 
the identification of this parameter using a model can suffer 
from inaccuracies. However, the model used has been widely 
validated in clinical use (Dickson et al., 2013; Penning et al., 
2012; Stewart, et al., 2016), and shown high performance in 
the clinical ranges observed here, minimizing such potential 
inaccuracies. 
The authors did not find any analyses comparing endogenous 
glucose production and insulin secretion between sexes in 
critically ill adults. However, due to their acute condition, 
these parameters could differ in many ways. Such analyses 
would allow comparison of this study results, first to suggest 
women could be more resistant to insulin than men, 
potentially due to a greater response to insult induced stress.  
 
 
     
 
The clinical impact of these results could be limited due to 
the retrospective data used here. However, this cohort is 
representative of a large generalised ICU cohort of patients 
from many years of GC practice.  
5.  CONCLUSIONS 
This study shows a significant difference in SI levels between 
males and females exists for ICU adults under insulin 
therapy. Females are more insulin resistant, and this could be 
due to a higher metabolic response to stress. 
Metabolic variability, %ΔSI, is equivalent between males and 
females. Both groups are thus equally controllable and should 
benefit from similar GC outcomes. In turn, insulin 
requirements for females are likely higher, but equal safety 
and efficacy should be achieved for both groups in GC. These 
results also potentially add a new dimension for future 
personalized medicine, and support the use of dynamic, 
model-based, personalised GC protocol designs. 
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